secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005124
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q4 2022 GAAP loss $0.80/share; core revenue up 97% YoY to $55M
-------------------------------------------------------------------------------

- Q4 total revenue $67.7M; core revenue (ex-COVID) $55.0M, up 97% YoY.
- GAAP net loss $23.8M ($0.80 per share); non-GAAP loss $14.2M ($0.48 per share).
- Full year 2022 core revenue $181.5M, up 95% YoY; total revenue $619.0M.
- Cash and investments $872.0M as of Dec 31, 2022; repurchased 815k shares in Q4.
- Full year GAAP net income $143.4M ($4.63 per share); adjusted EBITDA $257.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023005124/0000950170-23-005124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023005124/flgt-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer